Trophectoderm Sampling
A small number of cells are typically biopsied from a blastocyst and sent for genetic analysis while the embryo remains cryopreserved.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (PGT-A, PGT-M, PGT-SR, PGT-P / Emerging Testing), By Application (Aneuploidy Screening, Monogenic Disease Avoidance, Structural Rearrangement Detection, HLA Matching / Other Approved Applications), By End User (Fertility Clinics, Hospital-Based Reproductive Medicine Centers, Independent Genetic Laboratories, Research & Academic Institutes), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, aCGH / SNP Microarray, FISH / Other Methods), By Product / Service (Reagents & Consumables, Instruments, Software & Bioinformatics, Testing Services), and Regional Forecast, 2026-2034
The global preimplantation genetics diagnosis market was valued at USD 101.6 million in 2025 and is estimated at USD 105.3 million in 2026. The market is projected to reach USD 140.3 million by 2034, representing a 3.7% CAGR during 2026–2034.
Preimplantation genetic diagnosis, now more commonly grouped within preimplantation genetic testing, analyzes cells biopsied from IVF embryos before transfer. Modern clinical categories include PGT-M for monogenic disorders, PGT-SR for structural chromosomal rearrangements and PGT-A for chromosome copy-number screening, while PGT-P remains a newer and ethically debated application.
The clinical scope continues to expand. HFEA states that PGT-M can currently be used to avoid more than 2,000 approved genetic conditions, and September 2025 authority papers cited 1,982 approved PGT-M conditions at that point in time. This demonstrates how broader variant knowledge and family-specific assay development are expanding the range of inherited disorders that can be addressed before embryo transfer.
Technology is increasingly NGS-centered. Thermo Fisher notes that NGS is commonly used in PGT because of genomic resolution, scalability and the ability to combine testing modalities. CooperSurgical reports more than 15,000 PGT-M cases across more than 1,000 disorders in the last ten years and continues to update amplification and reporting workflows, illustrating ongoing commercial investment in faster, more integrated embryo testing.
Source: HFEA approved PGT-M conditions; HFEA authority papers; ASRM PGT-A committee opinion; CooperSurgical PGT-M; Thermo Fisher PGT with NGS.
The study defines the global preimplantation genetics diagnosis (pgd) market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | PGT-A; PGT-M; PGT-SR; PGT-P / Emerging Testing |
| By Application | Aneuploidy Screening; Monogenic Disease Avoidance; Structural Rearrangement Detection; HLA Matching / Other Approved Applications |
| By End User | Fertility Clinics; Hospital-Based Reproductive Medicine Centers; Independent Genetic Laboratories; Research & Academic Institutes |
| By Technology | Next-Generation Sequencing; Polymerase Chain Reaction; aCGH / SNP Microarray; FISH / Other Methods |
| By Product / Service | Reagents & Consumables; Instruments; Software & Bioinformatics; Testing Services |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; United Kingdom; Spain; Germany; France; Italy; China; Japan; India; South Korea; Australia; Brazil; UAE and other relevant markets |
| Key Market Players | CooperSurgical / CooperGenomics; Thermo Fisher Scientific; Illumina; Vitrolife / IGENOMIX; Labcorp; BGI Genomics; Roche; Natera; Quest Diagnostics |
The market includes genetic testing products and services used to analyze embryo biopsy samples before transfer during IVF. The scope covers PGT-A, PGT-M, PGT-SR and emerging PGT categories together with instruments, reagents, software and laboratory services directly used in embryo genetic testing.
IVF drugs, embryo culture media, incubators, genetic counseling without testing, prenatal diagnostics after implantation and general reproductive carrier screening are outside the core revenue boundary unless they directly support the PGT workflow.
HFEA states PGT-M can be used for more than 2,000 genetic conditions. Each additional clinically validated condition expands the number of families for whom embryo testing can be considered.
PGT is performed within IVF, so market growth is linked to assisted-reproduction use, embryo availability and maternal age. Older maternal age increases the likelihood of embryo aneuploidy, which can increase interest in chromosome screening.
NGS can assess whole-chromosome copy number, segmental abnormalities and targeted variants from small embryo-biopsy samples. This creates opportunities to combine PGT-A with PGT-M or PGT-SR within one laboratory workflow.
ASRM states that the value of PGT-A as routine screening for all IVF patients has not been demonstrated, while HFEA rates PGT-A green for reducing miscarriage but red for improving the chance of a baby for most fertility patients. This keeps use individualized.
PGT-P and elective embryo selection raise distinct ethical and clinical-validity questions. ASRM’s 2026 ethics opinion stresses current limits and rejects nonmedical trait selection as part of reproductive medicine.
Source: HFEA PGT-M; ASRM PGT-A; HFEA PGT-A; ASRM PGT-P.
CooperSurgical promotes a four-week Fast-Track PGT-M service and has standardized combined PGT-M and PGT-A reporting options, indicating a shift toward simpler ordering and shorter preparation timelines.
NGS can evaluate chromosome copy number and targeted variants at higher scale than FISH and many array workflows. Legacy techniques remain relevant in selected laboratories but are losing strategic importance.
ESHRE is revising its Good Practice Recommendations for organization of PGT, embryo biopsy, PGT-M and structural or numerical chromosomal testing, with stakeholder review active in 2026.
Professional guidance increasingly distinguishes miscarriage reduction from live-birth improvement. This encourages clinics to frame PGT-A around patient-specific circumstances rather than a universal IVF add-on.
ASRM’s 2026 opinion recognizes theoretical disease-risk applications but emphasizes scientific and ethical limits, keeping PGT-P outside mainstream standard-of-care use.
Source: CooperSurgical PGT-M; CooperSurgical PGT-A; ESHRE update; HFEA PGT-A; ASRM PGT-P.
Modern PGT combines embryo biopsy, DNA amplification, sequencing or targeted analysis, bioinformatics and genetic interpretation. Laboratory quality and result interpretation are as important as sequencing throughput.
A small number of cells are typically biopsied from a blastocyst and sent for genetic analysis while the embryo remains cryopreserved.
Because biopsy samples contain very little DNA, amplification is required before chromosome or variant analysis.
NGS is increasingly central, while PCR and array-based methods remain important for targeted or laboratory-specific workflows.
Copy-number, mosaicism, inheritance and family-specific variant interpretation require validated algorithms and specialist review.
Source: Thermo Fisher PGT; CooperSurgical PGT-A; CooperSurgical PGT-M.
By type, the market is segmented into PGT-A, PGT-M, PGT-SR and emerging PGT-P. PGT-A represents the broadest testing volume, while PGT-M remains the most clearly diagnostic family-specific use for serious inherited disorders.
PGT-A screens embryo biopsy samples for chromosome copy-number abnormalities. Use is common in IVF but professional bodies emphasize patient-specific decision-making rather than universal application.
PGT-M identifies whether embryos inherited a known familial monogenic disorder and can substantially reduce transmission risk when a suitable unaffected embryo is available.
PGT-SR evaluates embryos from carriers of balanced structural rearrangements to identify embryos with balanced or normal chromosome content.
PGT-P estimates polygenic disease risk from embryo genotypes but remains ethically and scientifically contested and is not a routine standard-of-care category.
PGT-A will remain the largest testing-volume segment, while PGT-M and PGT-SR provide stronger condition-specific clinical rationale and PGT-P remains a carefully limited emerging area.
By application, the market is segmented into aneuploidy screening, monogenic disease avoidance, structural rearrangement detection and HLA matching or other approved uses. Aneuploidy screening drives the largest volume, while monogenic disease avoidance provides the clearest disease-prevention use case.
Embryos are assessed for chromosome gains or losses before transfer. The main potential benefit is improved embryo selection and reduced miscarriage in selected patients.
Family-specific testing is used for serious inherited disorders such as cystic fibrosis, Huntington disease and many other approved conditions.
PGT-SR is used where a parent carries a structural chromosome rearrangement that can lead to unbalanced embryos.
Selected jurisdictions allow tissue typing and other carefully regulated applications when legal and clinical criteria are met.
Aneuploidy screening will remain the largest application by test volume, while monogenic disease avoidance and structural-rearrangement testing sustain high-value specialist demand.
By end user, demand is segmented across fertility clinics, hospital reproductive-medicine centers, independent genetic laboratories and research institutions. Fertility clinics are the leading end user because they generate the embryo-biopsy samples and coordinate patient treatment.
IVF clinics counsel patients, perform embryo biopsy and coordinate transfer, making them the main commercial referral source for PGT laboratories.
Academic and hospital fertility programs combine IVF, genetics and maternal-fetal medicine and often manage complex inherited-disease cases.
Central laboratories provide high-throughput sequencing, family-specific assay development and interpretation for multiple fertility centers.
Academic centers support validation, mosaicism research, new sequencing methods and investigation of emerging PGT applications.
Fertility clinics will remain the largest referral base, while specialized laboratories capture substantial value through centralized sequencing and interpretation.
By technology, the market is segmented into NGS, PCR, aCGH or SNP microarray, and FISH or other legacy methods. NGS is the leading technology because it supports high-resolution chromosome analysis and can integrate several test objectives in one workflow.
NGS provides scalable chromosome copy-number assessment and can support targeted variant analysis, making it central to current PGT-A, PGT-M and PGT-SR workflows.
PCR remains important for family-specific variants, haplotyping and targeted validation, particularly within PGT-M workflows.
Arrays remain established for chromosome copy-number and SNP-based analysis but face strategic pressure from flexible NGS workflows.
FISH has largely been displaced for broad chromosome screening but remains relevant historically and in selected targeted applications.
NGS will remain the dominant technology, while PCR continues to provide important family-specific value and array or FISH methods gradually lose share.
By product and service, the market is segmented into reagents and consumables, instruments, software and bioinformatics, and testing services. Testing services form the most visible commercial category because many clinics outsource embryo genetics to centralized laboratories.
Amplification kits, library-preparation reagents and sequencing consumables generate recurring demand with every embryo biopsy.
Sequencers, PCR platforms and automated laboratory equipment support testing scale and quality but have longer replacement cycles.
Copy-number analysis, haplotyping, mosaic interpretation and reporting increasingly depend on validated software and genomic pipelines.
Central laboratories design family-specific assays, sequence embryo samples and issue reports for fertility clinics, capturing high value without requiring each clinic to build a full genetics laboratory.
Testing services and consumables should remain the largest recurring value pools, while software and bioinformatics gain strategic importance as interpretation becomes more complex.
Regional demand follows IVF utilization, genetic-testing access, reimbursement, regulation and cultural acceptance. North America is the largest market, Europe has mature regulatory frameworks, and Asia-Pacific provides strong long-term expansion potential.
North America leads through high IVF volumes, large genetic-testing laboratories and rapid adoption of NGS-based embryo testing.
Europe combines sophisticated IVF services with country-specific rules on embryo testing. ESHRE provides a major professional framework for laboratory practice.
China, Japan, India and Australia are expanding IVF and reproductive genetics, although regulation and permitted applications vary.
Private fertility centers in Brazil, Mexico and other markets are expanding access, while cost remains an important barrier.
Gulf fertility hubs support advanced reproductive genetics, while broader regional access remains uneven.
Source: HFEA; ESHRE PGT Consortium; ASRM PGT-A.
PGT sits at the intersection of reproductive medicine and genetics, so market development is shaped by clinical evidence, laboratory standards, embryo-testing law and ethical boundaries.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| PGT-M regulation | HFEA requires condition-specific authorization for serious inherited disorders and maintains a current approved list. | Creates a structured pathway for disease-focused embryo testing in the UK. |
| PGT-A evidence caution | HFEA rates PGT-A green for reducing miscarriage but red for improving the chance of a baby for most fertility patients. | Supports selective rather than universal use. |
| ASRM PGT-A guidance | ASRM states routine PGT-A for all IVF patients has not demonstrated universal benefit. | Encourages patient-specific counseling. |
| PGT-P ethics | ASRM’s 2026 opinion emphasizes current limits and rejects nonmedical trait selection. | Keeps polygenic embryo screening outside mainstream routine care. |
Source: HFEA PGT-M; HFEA PGT-A; ASRM PGT-A; ASRM PGT-P.
The market is semi-consolidated around specialized reproductive-genetics laboratories and large sequencing or molecular-diagnostic suppliers. Competition centers on accuracy, turnaround time, assay breadth, family-specific test development, clinic integration and interpretation quality.
CooperSurgical offers PGT-A, PGT-M and PGT-SR services and reports more than 15,000 PGT-M cases across more than 1,000 disorders in the last decade.
Large molecular companies supply sequencing, amplification and laboratory platforms that support PGT workflows globally.
Specialized and diversified laboratories compete through broad clinic networks, testing services and regional reach.
Source: Cooper PGT-M; Thermo Fisher PGT; ESHRE.
September 2026: ESHRE kept stakeholder review open for updated Good Practice Recommendations covering PGT organization, embryo biopsy, PGT-M and structural or numerical chromosomal testing.
2026: ASRM published an ethics opinion on PGT-P, highlighting the scientific and ethical limits of polygenic embryo screening and rejecting nonmedical trait selection.
2026: CooperSurgical standardized PGT-M ordering and reporting options and included PGT-A within PGT-M case workflows with selectable reporting preferences.
2025–2026: HFEA’s active PGT-M list continued to expand beyond 2,000 genetic conditions, widening the potential family-specific testing population.
Source: ESHRE 2026 update; ASRM PGT-P; CooperSurgical updates; HFEA conditions.
The global preimplantation genetics diagnosis (pgd) market market is projected to grow from USD 105.3 million in 2026 to USD 140.3 million by 2034, at a 3.7% CAGR during 2026–2034. Growth is expected to remain steady rather than explosive because PGT is tied to IVF cycles, embryo availability and patient-specific indications. The most attractive growth areas are NGS-based integrated testing, faster PGT-M assay development, centralized laboratory services and broader access to condition-specific reproductive genetics.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Condition expansion | More than 2,000 PGT-M conditions are approved in the UK. | Broadens disease-focused use. |
| NGS adoption | NGS supports multiple PGT categories in one laboratory workflow. | Improves scalability. |
| IVF growth | PGT demand rises with assisted-reproduction cycles. | Expands the addressable testing pool. |
| Selective PGT-A | Guidance favors individualized use rather than universal screening. | Shapes realistic volume growth. |
| Faster PGT-M | Shorter assay-development timelines reduce treatment delay. | Improves patient and clinic experience. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global preimplantation genetics diagnosis (pgd) market landscape.
24LifeScience develops preimplantation genetics diagnosis (pgd) market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines the report’s defined PGD market scope with current HFEA, ESHRE and ASRM guidance plus primary laboratory and sequencing-platform information. Modern PGT terminology is used where it clarifies current clinical practice, while emerging applications are separated from established standard-of-care testing.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 101.6 million in 2025 and is estimated at USD 105.3 million in 2026. It is projected to reach USD 140.3 million by 2034 at a 3.7% CAGR during 2026–2034.
The field is now generally described as preimplantation genetic testing, including PGT-A, PGT-M and PGT-SR.
PGT-A represents the largest testing volume, while PGT-M provides the most clearly disease-specific family testing use.
North America is the largest regional market, supported by high IVF utilization and extensive genetic-testing infrastructure.
HFEA states PGT-M can currently be used to avoid more than 2,000 approved genetic conditions in the UK.
No. ASRM and HFEA emphasize that evidence does not support routine use for every patient and that benefits vary by clinical context.
NGS is the leading technology because it supports scalable chromosome analysis and can integrate multiple PGT objectives.
The report profiles CooperSurgical/CooperGenomics, Thermo Fisher, Illumina, Vitrolife/IGENOMIX, Labcorp, BGI Genomics, Roche, Natera and Quest Diagnostics.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.